Material Agreements

iSpecimen Inc. entered into Placement Agent Agreement with E.F. Hutton & Co. valued at Placement Agent agreed to act as the Company’s exclusive placement agent in connection with the Offe (effective 2025-12-30).

“In addition, in connection with the Offering, the Company entered into a Placement Agent Agreement, dated December 30, 2025 (the “Placement Agent Agreement”), with E.F. Hutton & Co. (the “Placement Agent”), pursuant to which the Placement Agent agreed to act as the Company’s exclusive placement agent in connection with the Offering, subject to the terms and conditions set forth therein.”

iSpecimen Inc. entered into Registration Rights Agreement with the Investors valued at Company agreed to provide certain registration rights with respect to the resale of the Conversion S (effective 2025-12-30).

“In connection with the Purchase Agreement, the Company also entered into a Registration Rights Agreement with the Investors (the “Registration Rights Agreement”), pursuant to which the Company agreed to provide certain registration rights with respect to the resale of the Conversion Shares, and agreed to file an initial registration statement within certain time periods as set forth in the Registration Rights Agreement to register the Conversion Shares.”

iSpecimen Inc. entered into Securities Purchase Agreement with certain accredited investors valued at 6,875 shares of Series C Convertible Non-Voting Preferred Stock having a stated value of $1,000 per (effective 2025-12-30).

“On December 30, 2025, iSpecimen Inc., a Delaware corporation (Nasdaq: ISPC) (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company agreed to sell, and the Investors agreed to purchase, 6,875 shares of the Company’s newly-designated Series C Convertible Non-Voting Preferred Stock, par value $0.0001 per share (the “Series C Preferred Stock”), having a stated value of $1,000 per share, at a purchase price of $800 per share.”

SKYX Platforms Corp. entered into Securities Purchase Agreements with an existing and a new strategic investor valued at $500,000 (effective 2025-12-30).

“On December 30, 2025, SKYX Platforms Corp. (the “Company”) signed and closed on Securities Purchase Agreements (the “Purchase Agreements”) from an existing and a new strategic investor for gross proceeds of $500,000.”

SKYX Platforms Corp. amended Note Amendment with a member of the Company’s Board of Directors valued at $835,900 (effective 2025-12-30).

“On December 30, 2025, the Company and the holder entered into an amendment to the Note (the “Note Amendment”), extending the maturity date to May 1, 2027, increasing the interest rate to ten percent (10%) per year, and adjusting the conversion price to $2.20 per share.”

Atara Biotherapeutics, Inc. amended Fourth Amendment with Pierre Fabre Medicament valued at from $40.0 million to $31.0 million (effective 2025-12-30).

“Under the terms of the Amendment, the Company has agreed to reduce the aggregate amount of potential milestone payments payable by Pierre Fabre to the Company upon achieving certain regulatory milestones relating to the approval by the FDA of a BLA for tab-cel from $40.0 million to $31.0 million for the right to receive an additional $15.0 million potential milestone payment from Pierre Fabre to the Company upon achieving a certain commercial milestone.”

Senseonics Holdings, Inc. amended Amended and Restated Collaboration and Commercialization Agreement with Ascensia Diabetes Care Holdings AG (effective 2025-12-31).

“In connection with entering into the Master Asset Purchase Agreement, Senseonics Inc. and the Seller entered into an Amended and Restated Collaboration and Commercialization Agreement (the “ A&R Collaboration Agreement ”) on the Execution Date, which amended and restated that certain Collaboration and Commercialization Agreement, dated August 9, 2020, between Senseonics Inc. and the Seller, as amended to date (the “ Existing Agreement ”).”

Senseonics Holdings, Inc. entered into Master Asset Purchase Agreement with Ascensia Diabetes Care Holdings AG valued at approximately $1.1 million (effective 2025-12-31).

“On December 31, 2025 (the “ Execution Date ”), Senseonics Holdings, Inc. (the “ Company ”), Senseonics, Incorporated, a wholly-owned subsidiary of the Company (“ Senseonics Inc. ” and together with the Company, the “ Purchaser Parties ”) and Ascensia Diabetes Care Holdings AG (the “ Seller ”) entered into a master asset purchase agreement (the “ Master Asset Purchase Agreement ”), pursuant to which, among other things, the Purchaser Parties agreed to acquire Seller’s and as applicable, Seller’s affiliates’, right, title and interest in and to certain assets related Seller’s marketing, selling and distribution of the Eversense® product in the United States”

Clipper Realty Inc. amended Loan Modification Agreement with Wells Fargo Bank, National Association, as trustee for the benefit of the registered holders of certain commercial mortgage pass-through certificates related to the Loan valued at approximately $2.2 million (effective 2025-12-30).

“On December 24, 2025, the Borrower, the Operating Partnership, and the Company entered into the Loan Modification Agreement (the “Agreement”) with Wells Fargo Bank, National Association, as trustee for the benefit of the registered holders of certain commercial mortgage pass-through certificates related to the Loan (collectively, the “Lender”), to settle the ongoing litigation between the Lender, the Borrower, the Company and the Operating Partnership. The Agreement became effective on December 30, 2025. Pursuant to the Agreement, the Borrower provided a $10 million renewal tenant reserve account letter of credit and paid fees of approximately $2.2 million to the special servicer and to counsel to the Lender, the Lender waived its claimed late charges and default interest, agreed to dismiss with prejudice the pending foreclosure actions, and approved the previously submitted five-year lease extension with the Property’s New York City tenant effective December 28, 2025.”

Cactus, Inc. entered into Amended and Restated Limited Liability Company Agreement with Baker Hughes Pressure Control Holdings LLC valued at Purchase Price funded using cash on hand; Exit Price based on 6x Adjusted EBITDA with max valuation.

“On the Closing Date, the Joint Venture, the Cactus Member, Baker Hughes Pressure Control Holdings LLC (the “ Baker Member ”), an indirect subsidiary of Baker Hughes Company, and, for the limited purposes specified therein, the Company and Baker Hughes Company, entered into an Amended and Restated Limited Liability Company Agreement of the Joint Venture (the “ LLC Agreement ”).”

INTELLIGENT BIO SOLUTIONS INC. entered into Securities Purchase Agreement with two healthcare focused institutional investors valued at approximately $10.0 million (effective 2025-12-31).

“On December 31, 2025, Intelligent Bio Solutions Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with two healthcare focused institutional investors for the sale by the Company of (i) 2,298,850 shares (the “Shares”) of the Company’s common stock (or Series L Pre-funded warrants in lieu thereof (the “Pre-Funded Warrants”)), par value $0.01 per share (the “Common Stock”), (ii) Series K-1 warrants to purchase up to an aggregate of 2,298,850 shares of Common Stock (the “Series K-1 Warrants”), and (iii) Series K-2 warrants to purchase up to an aggregate of 2,298,850 shares of Common Stock (the “Series K-2 Warrants” and, collectively with the Series K-1 Warrants and Pre-Funded Warrants, the “Warrants”), in a private placement offering (the “Offering”).”

MeiraGTx Holdings plc entered into Share Purchase Agreement with Perceptive Life Sciences Master Fund, Ltd. valued at $18,193,000 (effective 2025-12-31).

“On December 31, 2025, MeiraGTx Holdings plc (the “Company”) entered into a share purchase agreement (the “Share Purchase Agreement”) with Perceptive Life Sciences Master Fund, Ltd. (“Perceptive Master Fund”), an affiliate of Perceptive Advisors LLC (“Perceptive Advisors”), pursuant to which the Company agreed to purchase 2,300,000 of the Company’s ordinary shares, $0.00003881 par value per share (the “Ordinary Shares”), from Perceptive Master Fund at a price of $7.91 per share (which was the volume-weighted average price (VWAP) per share on the Nasdaq Global Select Market on December 31, 2025), for an aggregate purchase price of $18,193,000 (the “Share Repurchase”).”

CoreWeave, Inc. amended First Amendment with MUFG Bank, Ltd. (effective 2025-12-31).

“On December 31, 2025, CoreWeave Compute Acquisition Co. VII, LLC (“CCAC VII”), a Delaware limited liability company and a direct subsidiary of CoreWeave, Inc., a Delaware Corporation (the “Parent”), the Parent and CCAC VII Holdco LLC (“CCAC VII Holdco”), a Delaware limited liability company and a direct subsidiary of the Parent entered into an amendment (the “First Amendment”) to amend (i) that certain Credit Agreement, dated as of July 28, 2025 (the “DDTL 3.0 Credit Agreement”), by and among CCAC VII, as the initial borrower, CoreWeave Compute Acquisition Co. V, LLC, a Delaware limited liability company and a direct subsidiary of the Parent as the co-borrower, MUFG Bank, Ltd. as administrative agent, U.S. Bank Trust Company, National Association as collateral agent, U.S. Bank National Association, as depository bank and the lenders party thereto”

Baldwin Insurance Group, Inc. entered into Voting Agreement with certain direct owners of the Seller (Seller Group).

“On the Closing Date, pursuant to the Transaction Agreement, the Company entered into a voting agreement (the “Voting Agreement”) with certain direct owners of the Seller (the “Seller Group”).”

FARADAY FUTURE INTELLIGENT ELECTRIC INC. entered into Agreement with Warrant Holders (effective 2025-12-28).

“On December 28, 2025, Faraday Future Intelligent Electric Inc., a corporation incorporated under the laws of the State of Delaware (the “Company”) entered into warrant termination agreements (each, an “Agreement” and collectively, the “Agreements”) with holders (collectively, the “Warrant Holders”) of certain of the Company’s outstanding common stock purchase warrants”

PROG Holdings, Inc. amended Fourth Amendment with JPMorgan Chase Bank, N.A, as administrative agent valued at $125 million incremental term loan (effective 2026-01-02).

“On January 2, 2026, the Company entered into a fourth amendment (the "Fourth Amendment") to that certain credit agreement, dated November 24, 2020, by and among Progressive Finance Holdings, LLC, as borrower, the Company and certain subsidiaries of the Company, as guarantors, the several banks and other financial institutions from time to time party thereto and JPMorgan Chase Bank, N.A, as administrative agent (as amended, the "Credit Agreement").”

Energy Vault Holdings, Inc. amended A&R Registration Rights Agreement with YA II PN, Ltd. (effective 2025-12-30).

“on December 30, 2025, the Company and the Investor entered into an amendment and restatement of that certain registration rights agreement, by and among the Company and the Investor, dated September 22, 2025 (the “A&R Registration Rights Agreement”).”

Energy Vault Holdings, Inc. amended Amendment with YA II PN, Ltd. valued at $15.0 million (effective 2025-12-30).

“On December 30, 2025, the Company and the Investor entered into an amendment to the Purchase Agreement (the “Amendment”), pursuant to which the Company agreed to issue and sell an additional $15.0 million of Debentures to the Investor”

Hagerty, Inc. entered into Quota Share Agreement with Essentia Insurance Company (effective 2025-12-31).

“On December 31, 2025, HIA and Hagerty Re entered into a new Quota Share Reinsurance Agreement with Essentia (the “ Quota Share Agreement ”), effective January 1, 2026, pursuant to which Hagerty Re will assume 100% of the risk on policies (i) issued by Essentia on or after January 1, 2026 or (ii) issued by Essentia prior to January 1, 2026, the risk period under which remains unexpired as of January 1, 2026, with respect to losses for which the date of loss is on or after January 1, 2026.”

Hagerty, Inc. entered into General Agency Agreement with Essentia Insurance Company (effective 2025-12-31).

“On December 31, 2025, HIA and Hagerty Re, both subsidiaries of the Company, executed the General Agency Agreement with Essentia (the “ General Agency Agreement ”).”

Hagerty, Inc. amended Seventh Amended and Restated Limited Liability Company Agreement with Markel Group Inc. and the other members of OpCo (effective 2025-12-31).

“On December 31, 2025, the Company executed the Seventh Amended and Restated Limited Liability Company Agreement with Markel and the other members of OpCo (the “ Amended LLC Agreement ”), to among other things, remove certain restrictive covenants, including exclusivity provisions relating to the businesses of the Company and its subsidiaries.”

Hagerty, Inc. amended Sixth Amended and Restated Master Relationship Agreement with Markel Group Inc. (effective 2025-12-31).

“On December 31, 2025, the Company and OpCo, a subsidiary of the Company, entered into the Sixth Amended and Restated Master Relationship Agreement (the “ Relationship Agreement ”) with Markel, which amended and restated the Fifth Amended and Restated Master Alliance Agreement, dated December 18, 2023.”

Rani Therapeutics Holdings, Inc. terminated TRA Termination Agreement with InCube Labs, LLC (effective 2025-12-31).

“the Company entered into a Tax Receivable Agreement Termination and Release Agreement (the “TRA Termination Agreement”) by and between the Company and InCube Labs, LLC (acting on behalf of all the TRA Parties (as defined therein)), pursuant to which the parties agreed to terminate that certain Tax Receivable Agreement, dated August 3, 2021 (the “TRA”)”

Bausch & Lomb Corp amended Fourth Amendment with JPMorgan Chase Bank, N.A., as administrative agent, collateral agent, swingline lender and an issuing bank valued at $2,802,125,000 (effective 2026-01-02).

“On January 2, 2026, Bausch + Lomb Corporation (the “Company”) entered into an amendment (the “Fourth Amendment”) to the Credit and Guaranty Agreement, dated as of May 10, 2022 (as amended by the First Incremental Amendment, dated as of September 29, 2023, by the Second Incremental Amendment, dated as of November 1, 2024, by the Third Amendment, dated as of June 26, 2025, and as further amended, restated, supplemented or otherwise modified, refinanced or replaced from time to time, the “Credit Agreement”), by and among the Company, certain subsidiaries of the Company as subsidiary guarantors, the lenders and other persons party thereto, and JPMorgan Chase Bank, N.A., as administrative agent, collateral agent, swingline lender and an issuing bank.”

Crescent Energy Co entered into Crescent 2030 Notes Indenture with U.S. Bank Trust Company, National Association, as trustee valued at $237,179,000 aggregate principal amount.

“On the Settlement Date, the Issuer issued $237,179,000 aggregate principal amount of the Crescent 2030 Notes pursuant to that certain Indenture, dated as of the Settlement Date (the “Crescent 2030 Notes Indenture” and, together with the Crescent 2029 Notes Indenture, the “Crescent Notes Indentures”), among the Issuer, the Guarantors and the Trustee.”

Crescent Energy Co entered into Crescent 2029 Notes Indenture with U.S. Bank Trust Company, National Association, as trustee valued at $294,843,000 aggregate principal amount.

“On the Settlement Date, the Issuer issued $294,843,000 aggregate principal amount of the Crescent 2029 Notes pursuant to that certain Indenture, dated as of the Settlement Date (the “Crescent 2029 Notes Indenture”), among the Issuer, certain subsidiaries of the Issuer, as guarantors (the “Guarantors”), and U.S. Bank Trust Company, National Association , as trustee (the “Trustee”).”

Perimeter Solutions, Inc. entered into Indenture with U.S. Bank Trust Company, National Association valued at $550 million (effective 2026-01-02).

“under an indenture, dated January 2, 2026 (the “Indenture”), by and among Perimeter Holdings, the guarantors party thereto and U.S. Bank Trust Company, National Association, as trustee and notes collateral agent.”

CDT Equity Inc. entered into NJS Agreement with NJS Foresight Bio-Advisory, LLC valued at one-time fixed retainer of $150,000 (effective 2025-12-29).

“On December 29, 2025 (the “Effective Date”) the Company and NJS Foresight Bio-Advisory, LLC (“NJS”) entered into a Consulting Agreement (the “NJS Agreement,” together with the Thesprogen Agreement, the “Agreements”)”

CDT Equity Inc. entered into Thesprogen Agreement with Thesprogen, PC valued at $155,000 of consideration (effective 2025-12-28).

“On December 28, 2025, CDT Equity, Inc. (the “Company” or “CDT”) and Thesprogen, PC (“Thesprogen”) entered into a Consulting Agreement (the “Thesprogen Agreement”)”

Israel Acquisitions Corp entered into Waiver to Administrative Services Agreement with Israel Acquisitions Sponsor LLC valued at waiver of administrative fees, including $10,000 per month and $240,000 accrued fees (effective 2025-12-31).

“Item 1.01. Entry into a Material Definitive Agreement. On January 12, 2023, Israel Acquisitions Corp, a Cayman Islands exempted company (the “ Company ”) entered into an Administrative Services Agreement (the “ Agreement ”), with Israel Acquisitions Sponsor LLC (the “ Sponsor ”, together with the Company, the “ Parties ”). On December 31, 2025, the Parties entered into a waiver to the Agreement (the “ Waiver ”) whereby the Parties agreed to waive the administrative fees due under the Agreement. Pursuant to the Waiver, the waived administrative fees include (i) the $10,000 per month owed to the Sponsor until the consummation by the Company of an initial business combination or the Company’s liquidation, and (ii) the $240,000 accrued fees to date. The foregoing description of the Waiver is only a summary and is qualified in its entirety by reference to the full text of the Waiver, which is attached hereto as Exhibit 10.1, and incorporated by reference herein.”

Pelthos Therapeutics Inc. entered into Asset Purchase Agreement with Hatchtech Pty Ltd valued at $1,800,000 aggregate purchase price (including $450,000 down payment paid on November 20, 2025 and $ (effective 2025-12-23).

“On December 23, 2025, Pelthos Therapeutics Inc., a Nevada corporation (the “ Company ”) entered into an Asset Purchase Agreement (the “ Asset Purchase Agreement ”) with Hatchtech Pty Ltd ACN 098 559 409, an Australian corporation (“ Hatchtech ”), pursuant to which Hatchtech sold all of its right, title and interest in (i) the product developed by Hatchtech with Abametapir as its sole active ingredient for the treatment of head lice infestation in humans (the “ Xeglyze Product ”), (ii) all intangible assets of Hatchtech including intellectual property of Hatchtech relating to the Xeglyze Product, including, without limitation (A) certain patent and patent applications, together with all issuances, divisions, continuations, continuations-in-part, reissues, extensions, reexaminations, and renewals and (B) certain trademarks, service marks, trade names and registered user names, including registrations and applications for registration thereof, together with all goodwill associated therewi”

Blackstone Private Equity Strategies Fund L.P. entered into Amended and Restated Investment Management Agreement with Blackstone Private Investments Advisors L.L.C. valued at Management fee of 1.25% on Class I-Series I Units, 1.05% on Class I-Series II Units, 0.95% on Class (effective 2026-01-01).

“On January 1, 2026, BXPE U.S. entered into an Amended and Restated Investment Management Agreement (the “Investment Management Agreement”) with Blackstone Private Investments Advisors L.L.C. (the “Investment Manager”), to make certain updates reflecting the designation of the Class I-Series II Units and Class I-Series III Units.”

Fortress Net Lease REIT entered into Subsidiary Loan Agreement with Bank of America, N.A., as administrative agent valued at $111,100,000 (effective 2025-12-23).

“On December 23, 2025, FNLR Print LLC, a Delaware limited liability company (the “ Borrower ”), an indirect, wholly-owned subsidiary of Fortress Net Lease REIT (the “ Company ”), entered into a Loan Agreement (the “ Subsidiary Loan Agreement ”) with Bank of America, N.A., as administrative agent (in such capacity, the “ Administrative Agent ”), and the lenders from time to time party thereto.”

Fusemachines Inc. entered into Securities Purchase Agreement with Consilium Frontier Equity Fund LP (effective 2025-12-23).

“On December 23, 2025, Fusemachines Inc. (the " Company ") entered into a securities purchase agreement (the " Securities Purchase Agreement ") with Consilium Frontier Equity Fund LP”

Legence Corp. amended Amendment No. 12 with Legence Holdings LLC, Jefferies Finance LLC valued at $200 million (effective 2026-01-02).

“On January 2, 2026, Legence Holdings LLC (“Legence Holdings”), an indirect subsidiary of the Company, and certain other subsidiaries of the Company entered into Amendment No. 12 (the “Amendment”) to that certain Credit Agreement, dated as of December 16, 2020, by and among Legence Holdings, as borrower, Jefferies Finance LLC, as administrative agent, collateral agent, swing line lender and an L/C issuer, the guarantors party thereto from time to time and the lenders party thereto from time to time (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Credit Agreement”).”

Pinnacle Financial Partners, Inc. entered into Legacy Pinnacle Supplemental Indenture with U.S. Bank Trust Company, National Association.

“entered into a supplemental indenture (the “Legacy Pinnacle Supplemental Indenture”) with respect to Legacy Pinnacle’s 4.125% Fixed to Floating Rate Subordinated Notes due 2029”

Pinnacle Financial Partners, Inc. entered into Assumption Agreements with The Bank of New York Mellon, N.A..

“entered into assumption agreements (collectively, the “Assumption Agreements”) with respect to each of Synovus Bank’s: (i) 5.625% Senior Bank Notes due 2028 and (ii) 5.957% Fixed-to-Fixed Rate Subordinated Bank Notes due 2036”

Pinnacle Financial Partners, Inc. entered into Synovus Supplemental Indentures with The Bank of New York Mellon, N.A..

“entered into supplemental indentures (collectively, the “Synovus Supplemental Indentures”) with respect to each of Synovus’: (i) 6.168% Fixed Rate / Floating Rate Senior Notes due 2030, (ii) 5.900% Fixed-to-Fixed Rate Subordinated Notes due 2029 and (iii) Junior Subordinated Debt Securities due 2035”

TELOS CORP amended Second Amendment to Credit Agreement with JPMorgan Chase Bank, N.A., as Administrative Agent and Lender valued at $15,000,000 (effective 2025-12-30).

“On December 30, 2025, Telos Corporation (the “Company”) entered into a Second Amendment to Credit Agreement (the “Second Amendment”) with JPMorgan Chase Bank, N.A., as Administrative Agent and Lender.”

QHSLab, Inc. amended Promissory Note Modification and Partial Conversion Agreement with Alex Mirakian MD PA (effective 2025-12-31).

“On December 31, 2025, QHSLab, Inc., (the Company), entered into a Promissory Note Modification and Partial Conversion Agreement (the Modification Agreement) with Alex Mirakian MD PA (the Holder), in connection with a previously issued convertible promissory note dated May 7, 2021 (the Original Note).”

Bausch Health Companies Inc. amended Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, collateral agent, swingline lender and an issuing bank (effective 2026-01-02).

“On January 2, 2026, Bausch + Lomb Corporation (“Bausch + Lomb”), a subsidiary of Bausch Health Companies Inc., entered into an amendment (the “Fourth Amendment”) to the Credit and Guaranty Agreement, dated as of May 10, 2022”

MGT CAPITAL INVESTMENTS, INC. entered into Agreement with several accredited investors valued at up to $1,000,000 (effective 2025-12-19).

“Between December 19, 2025, and December 23, 2025, MGT Capital Investments, Inc. (the “Company”) entered into Securities Purchase Agreements and related Subscription Agreements (collectively, the “Agreement”) with several accredited investors. Under the terms of the Agreement, the Company is conducting a private placement of up to $1,000,000 of its common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $0.001 per share.”

MERCANTILE BANK CORP entered into Credit Agreement with U.S. Bank National Association valued at $30.0 million (effective 2025-12-24).

“On December 24, 2025, Mercantile Bank Corporation, a Michigan corporation (“Mercantile”) entered into a Credit Agreement (the “Credit Agreement”) with U.S. Bank National Association, a national banking association. The Credit Agreement is for a $30.0 million term loan to fund the purchase price and related expenses of the Merger (defined below) and for working capital purposes.”

TAP REAL ESTATE TECHNOLOGIES, INC. entered into License Agreement with TAP, Inc. (effective 2025-12-30).

“ecember 30, 2025, the Company entered into a License Agreement (the “License Agreement”) with TAP, Inc. (“TAP”). Pursuant to the License Agreement, the Company licensed from TAP the right to use TAP’s technology platform for use in the vertical”

TAP REAL ESTATE TECHNOLOGIES, INC. entered into Convertible Promissory Note with H-Cap Investments, LLC valued at $550,000 Convertible Promissory Note (effective 2025-12-29).

“On December 29, 2025, HUMBL, Inc. (the “Company”) issued a $550,000 Convertible Promissory Note (the “Note”) to H-Cap Investments, LLC.”

COMSCORE, INC. entered into Second Amended and Restated Stockholders Agreement with the Company and the Stockholders.

“Stockholders Agreement On the Closing Date, the Company and the Stockholders entered into a Second Amended and Restated Stockholders Agreement (the "Stockholders Agreement"), pursuant to which, among other things, immediately following the Closing, the Company was obligated to take all necessary action to ensure that the Company's Board of Directors (the "Board") and certain committees thereof consisted of the individuals set forth therein, including the applicable designees of each Stockholder, in each case as more particularly set forth in the Stockholders Agreement.”

Riot Platforms, Inc. terminated 2024 Sales Agreement with Cantor Fitzgerald & Co., B. Riley Securities, Inc., BTIG, LLC, Roth Capital Partners, LLC, Keefe, Bruyette & Woods, Inc., as successor in interest to Stifel Nicolaus Canada Inc., Compass Point Research & Trading, LLC, Northland Securities, Inc., and ATB Capital Markets USA Inc. valued at terminated effective December 30, 2025 (effective 2025-12-30).

“Effective as of December 30, 2025, the Company terminated the prior sales agreement, dated as of August 9, 2024 (the “ 2024 Sales Agreement ”), with Cantor Fitzgerald & Co., B. Riley Securities, Inc., BTIG, LLC, Roth Capital Partners, LLC, Keefe, Bruyette & Woods, Inc., as successor in interest to Stifel Nicolaus Canada Inc., Compass Point Research & Trading, LLC, Northland Securities, Inc., and ATB Capital Markets USA Inc., a copy of which is filed as Exhibit 1.1 to the Company’s current report on Form 8-K filed with the SEC on August 9, 2024.”

Riot Platforms, Inc. entered into 2025 Sales Agreement with B. Riley Securities, Inc., BTIG, LLC, Cantor Fitzgerald & Co., Keefe, Bruyette & Woods, Inc., Macquarie Capital (USA) Inc., Morgan Stanley & Co. LLC, Needham & Company, LLC, Northland Securities, Inc., and Roth Capital Partners, LLC valued at up to $500,000,000 (effective 2025-12-30).

“On December 30, 2025, Riot Platforms, Inc. (“ Riot ”, the “ Company ”, “ we ”, “ us ”, “ our ”, etc.) entered into a sales agreement, dated as of December 30, 2025 (the “ 2025 Sales Agreement ”), with the sales agents identified therein: B. Riley Securities, Inc., BTIG, LLC, Cantor Fitzgerald & Co., Keefe, Bruyette & Woods, Inc., Macquarie Capital (USA) Inc., Morgan Stanley & Co. LLC, Needham & Company, LLC, Northland Securities, Inc., and Roth Capital Partners, LLC (collectively, the “ Sales Agents ”). Pursuant to the 2025 Sales Agreement, we may offer and sell, to or through the Sales Agents, an indeterminate number of shares of Riot’s common stock, no par value per share (“ Common Stock ”), having an aggregate initial offering price of up to $500,000,000 (the “ Placement Shares ”) at prevailing market prices from time to time, in an “at-the-market offering” within the meaning of Rule 415 of the Securities Act of 1933, as amended (the “ Securities Act ”), including sales made to the”

Fluent, Inc. entered into At-The-Market Issuance Sales Agreement with Lake Street Capital Markets, LLC valued at aggregate sales price of up to approximately $11,200,000 (effective 2025-12-31).

“On December 31, 2025, Fluent, Inc. (the “Company”) entered into an At-The-Market Issuance Sales Agreement (the “ATM Agreement”) with Lake Street Capital Markets, LLC (“Lake Street”), under which the Company may offer and sell shares of its common stock, par value $0.0005 per share (the “Shares”), having an aggregate sales price of up to approximately $11,200,000 through Lake Street as the sales agent.”

Groupon, Inc. entered into framework agreement with Italian tax authorities valued at approximately $25.2 million (€21.5 million) (effective 2025-12-29).

“On December 29, 2025, Groupon Italy and the Italian tax authorities entered into a binding framework agreement that definitively resolves all outstanding tax disputes involving Groupon Italy”